Development and Validation of a Gradient RP-HPLC Method for Quantitative Determination of Potential Manufacturing Impurities in New Drug Apronalide and Pharmaceutical Formulations

Authors

  • Ritesh Mishra API Analytical Research & Development Department, Medilux Laboratories Pvt. Ltd. Pithampur, Dist. Dhar. (M.P.), India
  • Hitesh Malvia API Analytical Research & Development Department, Medilux Laboratories Pvt. Ltd. Pithampur, Dist. Dhar. (M.P.), India
  • M. Asif Khan API Analytical Research & Development Department, Medilux Laboratories Pvt. Ltd. Pithampur, Dist. Dhar. (M.P.), India

DOI:

https://doi.org/10.37591/rrjodfdp.v1i1.306

Abstract

Three impurities in apronalide drug substance were detected and quantified using a simple isocratic reverse phase HPLC method. The chromatographic separation was achieved on a Thermo Hypersil gold-CN, 100 A0 5 µm, and 250X4.6 mm using a mobile phase consisting of phosphate buffer (pH-4.6) - Methanol with UV detection at 210 nm and flow rate of 0.8 ml/min. The column temperature was maintained at 250C throughout the analysis. This method was rapid, simple for separation of apronalide and potential manufacturing impurities from each other in a 30 min run time.  To the best of our knowledge, none of the method has been reported in the any pharmacopeia and literature for separation of apronalide from the given set of related substances. The proposed method has been validated as per international guidelines on method validation and can be used for the routine quality control analysis of apronalide as active pharmaceutical ingredient (API) and pharmaceutical formulations. Also the method was determined to be robust with regards to the following parameters: mobile phase apparent pH; mobile phase organic content; detection wavelength and time dependence of sample and standard stability. 

 

Keywords: Apronalide, related Substances, HPLC, pharmaceutical formulation, drug

 

Downloads

Published

2019-02-25

Issue

Vol. 1 No. 1 (2014)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.